The purpose of this research is to find out whether the study medication denosumab can help prevent breast cancer in women with a BRCA1 mutation. The research also aims to find out whether denosumab decreases the risk of developing ovarian cancer or other types of cancer, study the safety of using denosumab, and study its effect on bone health.
The study is a randomised, double-blind, placebo-controlled study. This means that participants will receive an injection of either denosumab or placebo (no drug) every 6 months for 5 years. Participants will need to visit their study doctor every 6 months while receiving the medication and will continue to be checked by their study team every 12 months for a further 5 years (total of 10 years).
The purpose of this study is to compare the effects, good or bad, of combination immunotherapy (atezolizumab plus bevacizumab) versus observation (not receiving any treatment) on participants with completely resected or ablated hepatocellular cancer (HCC) who are at high risk for disease recurrence. In this study, patients will receive either atezolizumab plus bevacizumab or no treatment.
Both mania and psychosis can involve changes to a person’s mood, thinking, and behaviour and can impact a person’s social life and participation in work or education. These mental health conditions not only affect the person who has the disorder but also the lives of family members and friends who help support them.
By completing this survey, you will be contributing to a better understanding of caregiver and sibling experiences. This information will be particularly helpful for working out ways to better support caregivers and siblings.
The main purpose of this research project is to look at whether the trial drug, sodium selenate decreases the rate of brain shrinkage in patients with fronto-temporal dementia. The research project will also look into the effect of sodium selenate on brain function and markers of disease measured on brain scans, in blood, and in the fluid around the brain and spine to see if participants are responding to the treatment.
The primary purpose of this study is to help answer the following research questions:
- How safe mirikizumab is and whether you might have any side effects when you take it?
- How effective mirikizumab is as a treatment for Crohn’s disease when other medications may not work?
- How mirikizumab compares to ustekinumab (a current treatment for Crohn's Disease) or placebo?
Anticipated date that enrolment will close: 31 December 2022
Tourette Syndrome (TS) is a neurological (brain) disorder characterised by rapid, repetitive, and involuntary muscle movements and vocalisations (tics), often involving behavioural difficulties including attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Although TS rare, it is 2-4 times more common in males and is most prominent during childhood and adolescence.
Current treatments for TS are antipsychotic drugs which are often only moderately effective and result in a high incidence of side effects.
The investigational product, NOE-105 inhibits a specific enzyme in the body (PDE10A). The inhibition of PDE10A in the brain may lead to a reduction in the number of tics in people with TS by helping to provide a balance in the number of motor neurons (brain cells that are believed to control the tics) in the brain.
This is an open-label study which means both the researchers and study participants know which treatment is being given. All participants will receive the NOE-105 investigational product. NOE-105 will be given to participants once a day for a maximum of 12 weeks.
Anticipated date that enrolment will close: 2022 - month to be confirmed
This is a study of an experimental treatment (referred to as “study drug”) called CVL-751 as a possible treatment for Parkinson’s disease. An experimental treatment is one that has not been approved by the United States (US) Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA) in Australia or any other regulatory agency .
The main purpose of this study is to learn how well the study drug works and how safe the study drug is and to find the right dose. If you choose to participate in this study, you may receive the study drug, or you may receive placebo. A placebo is a medication with no active ingredients. It looks like the real thing but is not. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
Anticipated date that enrolment will close: 31 December 2021
Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease. The main purpose of this study is to learn how safe the study is and how well it works. This is a randomised, double-blinded trial for people in the early stages of Parkinson's disease.